Preclinical hunting ground
Why Pfizer established a dedicated group for preclinical investment
With a new dedicated preclinical investment initiative, Pfizer Inc. is hoping to more systematically evaluate and invest in the large number of opportunities that fall between its academic translational research collaborations and its venture arm.
Under the new initiative, known informally as Pfizer's R&D Innovate concept, Pfizer plans to make equity investments and incubate companies with platforms or assets it considers strategically important.
Pfizer already has groups dedicated to tapping into external innovation in very early and late-stage R&D. Since 2010, the pharma's Centers for Therapeutic Innovation (CTI) have put labs, company scientists and drug discovery technologies near academic partners to support translational research.
Pfizer Venture Investments, which debuted in 2004, invests in companies that tend to be beyond their series A rounds.
Uwe Schoenbeck, who